company background image
TNGX logo

Tango Therapeutics NasdaqGM:TNGX Stock Report

Last Price

US$2.98

Market Cap

US$334.1m

7D

-2.0%

1Y

-76.9%

Updated

31 Jan, 2025

Data

Company Financials +

Tango Therapeutics, Inc.

NasdaqGM:TNGX Stock Report

Market Cap: US$334.1m

TNGX Stock Overview

A biotechnology company, discovers and develops drugs for the treatment of cancer. More details

TNGX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Tango Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tango Therapeutics
Historical stock prices
Current Share PriceUS$2.98
52 Week HighUS$12.99
52 Week LowUS$2.59
Beta0.81
1 Month Change-3.56%
3 Month Change-42.14%
1 Year Change-76.86%
3 Year Change-65.94%
5 Year Changen/a
Change since IPO-70.87%

Recent News & Updates

Recent updates

Tango Therapeutics: Chance For A Short Squeeze

Jan 23

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Dec 05
Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Oct 31
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Sep 10

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Sep 01
What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Jun 29
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

May 30
Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Mar 19
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Mar 06
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Jan 08
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Nov 09
Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Aug 12
New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

May 10
Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

Oct 20

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Oct 05
Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 13
Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Aug 10

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

May 28
We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Jan 06
We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Shareholder Returns

TNGXUS BiotechsUS Market
7D-2.0%0.6%-0.5%
1Y-76.9%-3.8%24.3%

Return vs Industry: TNGX underperformed the US Biotechs industry which returned -3.8% over the past year.

Return vs Market: TNGX underperformed the US Market which returned 24.3% over the past year.

Price Volatility

Is TNGX's price volatile compared to industry and market?
TNGX volatility
TNGX Average Weekly Movement16.5%
Biotechs Industry Average Movement11.4%
Market Average Movement6.5%
10% most volatile stocks in US Market18.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: TNGX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: TNGX's weekly volatility has increased from 11% to 16% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017140Barbara Weberwww.tangotx.com

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.

Tango Therapeutics, Inc. Fundamentals Summary

How do Tango Therapeutics's earnings and revenue compare to its market cap?
TNGX fundamental statistics
Market capUS$334.07m
Earnings (TTM)-US$123.39m
Revenue (TTM)US$43.38m

7.4x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TNGX income statement (TTM)
RevenueUS$43.38m
Cost of RevenueUS$141.32m
Gross Profit-US$97.94m
Other ExpensesUS$25.46m
Earnings-US$123.39m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.15
Gross Margin-225.75%
Net Profit Margin-284.43%
Debt/Equity Ratio0%

How did TNGX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 00:53
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tango Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Yuan ZhiB. Riley Securities, Inc.
Eric SchmidtCantor Fitzgerald & Co.